MegaPro Biomedical Co., Ltd
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in precl… Read more
MegaPro Biomedical Co., Ltd (6827) - Net Assets
Latest net assets as of June 2025: NT$132.91 Million TWD
Based on the latest financial reports, MegaPro Biomedical Co., Ltd (6827) has net assets worth NT$132.91 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$162.36 Million) and total liabilities (NT$29.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$132.91 Million |
| % of Total Assets | 81.86% |
| Annual Growth Rate | -4.57% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 37.02 |
MegaPro Biomedical Co., Ltd - Net Assets Trend (2020–2024)
This chart illustrates how MegaPro Biomedical Co., Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MegaPro Biomedical Co., Ltd (2020–2024)
The table below shows the annual net assets of MegaPro Biomedical Co., Ltd from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$204.35 Million | -24.05% |
| 2023-12-31 | NT$269.07 Million | -14.40% |
| 2022-12-31 | NT$314.35 Million | -22.54% |
| 2021-12-31 | NT$405.84 Million | +64.73% |
| 2020-12-31 | NT$246.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MegaPro Biomedical Co., Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31744200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$647.21 Million | 316.71% |
| Other Components | NT$112.19 Million | 54.90% |
| Total Equity | NT$204.35 Million | 100.00% |
MegaPro Biomedical Co., Ltd Competitors by Market Cap
The table below lists competitors of MegaPro Biomedical Co., Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Han Chang Paper Co. Ltd.
KQ:009460
|
$3.23K |
|
Sunrays Textile Mills Ltd
KAR:SUTM
|
$3.23K |
|
Tinybuild Inc
LSE:TBLD
|
$3.23K |
|
MORNING LIGHT LTD
SEM:MOLI
|
$3.23K |
|
PetroVietnam Oil Phu Yen JSC
VN:PPY
|
$3.22K |
|
Zovio Inc
PINK:ZVOI
|
$3.21K |
|
Service Global
KAR:SGF
|
$3.21K |
|
Biafo Industries Ltd
KAR:BIFO
|
$3.21K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MegaPro Biomedical Co., Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 269,073,000 to 204,351,000, a change of -64,722,000 (-24.1%).
- Net loss of 164,041,000 reduced equity.
- New share issuances of 84,527,000 increased equity.
- Other comprehensive income decreased equity by 85,367,000.
- Other factors increased equity by 100,159,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-164.04 Million | -80.27% |
| Share Issuances | NT$84.53 Million | +41.36% |
| Other Comprehensive Income | NT$-85.37 Million | -41.77% |
| Other Changes | NT$100.16 Million | +49.01% |
| Total Change | NT$- | -24.05% |
Book Value vs Market Value Analysis
This analysis compares MegaPro Biomedical Co., Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.25x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.26x to 3.25x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$4.81 | NT$10.85 | x |
| 2021-12-31 | NT$7.51 | NT$10.85 | x |
| 2022-12-31 | NT$5.67 | NT$10.85 | x |
| 2023-12-31 | NT$5.19 | NT$10.85 | x |
| 2024-12-31 | NT$3.34 | NT$10.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MegaPro Biomedical Co., Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1171721.43%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-80.27%) is below the historical average (-49.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -60.42% | -2003.81% | 0.03x | 1.08x | NT$-173.50 Million |
| 2021 | -21.97% | 0.00% | 0.00x | 1.07x | NT$-129.73 Million |
| 2022 | -35.54% | 0.00% | 0.00x | 1.09x | NT$-143.16 Million |
| 2023 | -47.40% | -708600.00% | 0.00x | 1.09x | NT$-154.46 Million |
| 2024 | -80.27% | -1171721.43% | 0.00x | 1.10x | NT$-184.48 Million |
Industry Comparison
This section compares MegaPro Biomedical Co., Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MegaPro Biomedical Co., Ltd (6827) | NT$132.91 Million | -60.42% | 0.22x | $3.23K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |